Efficacy of felbamate in a cohort of patients with epilepsy with myoclonic atonic seizures (EMAtS).

Laurel Reed, Michael Ciliberto, Susan L Fong, Katherine Nickels, Eric Kossoff, Elaine Wirrell, Charuta Joshi

Epilepsy research 2024 Mar

filter terms:

Epilepsy with myoclonic atonic seizures (EMAtS) is a rare childhood onset developmental and epileptic encephalopathy which is frequently refractory to medical therapy. The optimal antiseizure medication remains unknown. This study reports the efficacy of felbamate in children with EMAtS. Six large pediatric epilepsy centers performed a retrospective chart review on patients diagnosed with EMAtS at their institutions and collected data on felbamate usage and efficacy. Responders were classified as patients who had a 50% or greater reduction in seizures with a given therapy. Out of 259 patients, 37 (14%) were treated with felbamate. The efficacy of felbamate was 62%, which was greater than that of either levetiracetam or valproic acid (15%, p < 0.001% and 32%, p = 0.001 respectively) and similar to that of the ketogenic diet (69%, p = 0.8). Felbamate appears to be an effective treatment for EMAtS and should be strongly considered in the treatment course of this disease. Copyright © 2024 Elsevier B.V. All rights reserved.

Citation

Laurel Reed, Michael Ciliberto, Susan L Fong, Katherine Nickels, Eric Kossoff, Elaine Wirrell, Charuta Joshi. Efficacy of felbamate in a cohort of patients with epilepsy with myoclonic atonic seizures (EMAtS). Epilepsy research. 2024 Mar;201:107314